4 / 8
Page 15
Notes:
allied
academies
Journal of Diabetology | Volume 3
Annual Summit on
Diabetes, Obesity & Heart
Diabetes, Endocrinology and Metabolic Syndrome
International Conference on
Joint Event
&
March 07-08, 2019 | London, UK
N
on-alcoholic fatty liver disease (NAFLD) is a distinct hepatic
condition characterized by abnormal fat accumulation
in liver cells. The term NAFLD is used to describe a wide array
of fatty liver changes from simple steatosis to steatohepatitis,
cirrhosis and hepatocellular carcinoma, in the absence of
excessive alcohol intake. It is one of the most common forms
of chronic liver disease in developed countries. With increasing
urbanization and behavioral changes such as decreased physical
activity, high-dense energy fat diet and increased occurrence of
type 2 diabetes mellitus (T2DM), its prevalence has increased
in the Asian region. The overall prevalence of NAFLD in western
countries varies from15-40%and in Asian countries from9-40%.
In India too, NAFLD is emerging as an important cause of liver
disease. Epidemiological studies suggest the prevalence of
NAFLD to be around 9-32% in general Indian population, with
a higher incidence amongst overweight/obese and diabetic/
prediabetic patients. NAFLD and its more severe form with
steatohepatitis (NASH), are common in patients with T2DM.
Compared to non-obese patients without NAFLD, patients with
NAFLD have severe systemic (liver/muscle), and particularly,
adipose tissue (fasting/postprandial) insulin resistance. NAFLD is
a well-known contributor for the development of cardiovascular
disease (CVD). CIMT is a known marker for early atherosclerosis
and its progression. In recent years, case-control studies have
shown a relationship between NAFLD and the presence of
early manifestations of atherosclerosis as indicated by CIMT
measurement. The first clinical manifestation of CVD often
arises in a stage of well-advanced atherosclerosis. The putative
underlying mechanisms that link NAFLD to cardiovascular,
cardiac and arrhythmogenic complications might originate
from the expanded and inflamed visceral adipose tissue. NAFLD
frequently coexists with obesity, diabetes, and dyslipidemia an
improved knowledge of the pathophysiological links of NAFLD
with cardiovascular, cardiac and arrhythmogenic complications
might also provide a potential target for the pharmacological
treatment of these diseases.
Speaker Biography
Sarita Bajaj is currently Director-Professor and Head of Medicine, MLN Medical College,
India. She has been awarded the Lifetime Achievement Award of the UP-Diabetes
Association (UPDA). Her major contribution is towards studies on diabetes, obesity and
growth. She has almost 200 publications in peer reviewed journals, monograms and books.
She has been awarded numerous Orations and Fellowships. In her capacity as scientific
chair, she has successfully organized well attended scientific programs on diabetes,
endocrine and metabolic disorders, diabetes exhibitions, camps and has been involved in
several National Diabetes Projects. She is holding and has held many prestigious posts of
National Societies across India. She is Editor in Chief, ESI Manual of Endocrinology 1st and
2nd edition and on the Editorial Committee of several peer reviewed journals. She has been
invited as faculty at both national & international forum. Honors have bestowed upon her
in the scientific and public field for her enormous contribution to themedical fraternity and
society in endocrine education and awareness.
e:
drsarita.bajaj@gmail.comSarita Bajaj
MLN Medical College, India
Non-alcoholic fatty liver disease: Associations and impact on cardiovascular events